Skip to main content

Table 4 Clinical efficacy and safety results for marbofloxacin and enrofloxacin in the treatment of APP associated respiratory disease in fattening pigs

From: Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

   Marbofloxacin Enrofloxacin CI of treatment difference
Absent Mild Moderate Severe Absent Mild Moderate Severe
Respiratory scores % [n]a Day 0 0.0 [0] 0.0 [0] 94.2 [114] 5.8 [7] 0.0 [0] 0.0 [0] 89.8 [106] 10.2 [12]  
  Day 2 43.0 [52] 53.7 [65] 2.5 [3] 0.8 [1] 46.2 [54] 49.6 [58] 4.3 [5] 0.0 [0]  
  Day 3 68.6 [83] 28.1 [34] 3.3 [4] 0 [0] 65.8 [77] 32.5 [38] 1.7 [2] 0 [0]  
  Day 7 94.2 [113] 5.8 [7] 0.0 [0] 0.0 [0] 93.2 [109] 6.8 [8] 0.0 [0] 0.0 [0]  
  Day 21 94.7 [108] 3.5 [4] 1.8 [2] 0.0 [0] 95.7 [110] 4.3 [5] 0.0 [0] 0.0 [0]  
Depression scores % [n]a Day 0 0.0 [0] 89.3 [108] 9.9 [12] 0.8 [1] 0.0 [0] 90.7 [107] 9.3 [11] 0.0 [0]  
  Day 2 59.5 [72] 38.0 [46] 2.5 [3] 0.0 [0] 59.8 [70] 40.2 [47] 0.0 [0] 0.0 [0]  
  Day 3 80.2 [97] 18.2 [22] 1.7 [2] 0 [0] 80.3 [94] 19.7 [23] 0 [0] 0 [0]  
  Day 7 90.8 [109] 9.2 [11] 0.0 [0] 0.0 [0] 92.3 [108] 7.7 [9] 0.0 [0] 0.0 [0]  
  Day 21 97.4 [111] 2.6 [3] 0.0 [0] 0.0 [0] 97.4 [112] 2.6 [3] 0.0 [0] 0.0 [0]  
Rectal temperatures °C Day 0 40.6 (0.41) [121] 40.6 (0.40) [118]  
  Day 2 39.6 (0.42) [121] 39.7 (0.36) [117] −0.05; 0.15
  Day 3 39.6 (0.49) [121] 39.6 (0.56) [117] −0.016; 0.11
  Day 7 39.4 (0.52) [120] 39.4 (0.51) [117] −0.12; 0.14
  Day 21 39.4 (0.43) [114] 39.5 (0.42) [115] 0.01; 0.23
Retreatment % animalsb Day 2 n/a 17.8 [21]  
Clinical cure % animalsb Day 7 81.8 [99] 81.4 [96] −9.37; 10.29
  Day 21 84.2 [101] 82.2 [97] −7.54; 11.47
SRD removals & mortalities %b Days 0–21 5.0 [6] 2.5 [3] −7.22; 2.38
SRD relapses % animalsb Days 8–21 0.0 [0] 1.0 [1] −0.99; 3.07
Adverse events % animals (CI)c   4.1 [5] 6.7 [8] −3.1; 8.3
Injection site reactions % animalsc 2.4 [3] 1.6 [2]  
Concurrent disorders % animalsc   0.0d [0] 7.5e [9]  
Live weight gain kg Days 0–21 19.81 (5.06) [114] 20.05 (7.03) [115] −0.026; 0.109
No. animals: Intention to treatc Day 0 122 120  
No. animals: Per protocolb Day 7 121 118  
  1. Results are for the overall study which included 4 farms and are shown as mean (standard deviation) unless indicated otherwise; CI confidence interval
  2. aRefer to Clinical examinations for detailed description of individual scores. [n] number of animals
  3. bIndicated efficacy data percentages are based on per protocol populations. Note that percentages for respiratory and depression scores, and rectal temperatures are based on numbers of animals in a treatment group on a given day, [n]
  4. cIndicated safety data percentages are based on intention to treat populations. There were no suspected adverse drug reactions
  5. d,evalues in a row are significantly different. n/a Not applicable
  6. Animals euthanised prior to study for diagnostic purposes are excluded from each of the populations